AAN report on status of MS drug trials – PART II
As the AAN conferences continues, so too do the updates on current and new treatments for MS. Here are some more highlights: Efficacy…
AAN report on status of MS drug trials – PART I
A large proportion of the AAN scientific program is centered on therapeutic advances. Whether it’s an early safety study, a phase II or…
Vitamin D, diet, and MS – is the answer in the gut?
One of the more interesting poster sessions I attended today here at AAN focused on risk factors in MS. In particular, there was…
Largest neurology conference in the world starts today
The 67th American Academy of Neurology Annual Meeting officially begins today here in beautiful Washington, D.C. Last year’s meeting in Philadelphia broke attendance…
Putting MS on Ice: Jordan Sigalet
Jordan may be a former NHL’er and now goaltending coach for the Calgary Flames, but he still faces the same issues many Canadians…
Research Decoder: The Blood-Brain Barrier
While reading about multiple sclerosis, you may have come across the blood-brain barrier and wondered what it’s all about. Many people think of…
Research Decoder: Remyelination versus Neuroprotection
Two words that I often see used interchangeably are remyelination and neuroprotection. Both processes are part of the body’s innate repair and damage…
What is MS?
Canada has one of the highest rates of multiple sclerosis (MS) in the world, with an estimated 77,000 Canadians living with the disease. While it is most often diagnosed in young adults aged 20 to 49, younger children and older adults are also diagnosed with the disease.